Crescent Biopharma (CBIO) vs Monopar Therapeutics (MNPR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Monopar Therapeutics (MNPR) over the past year, gaining 17.1% versus a loss of 14.8%. Over five years, MNPR leads with a +242.1% price change compared with -92.9% for CBIO. Crescent Biopharma is the larger company by market cap ($553.9 million vs $530.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CBIO | MNPR |
|---|---|---|
| Share price | $14.91 | $78.96 |
| Market cap | $553.86M | $529.99M |
| 1-day change | +5.59% | -5.98% |
| YTD return | +19.06% | +28.61% |
| 1-year return | +17.08% | -14.80% |
| 5-year return | -92.87% | +242.08% |
| EPS (TTM) | $-7.63 | $-2.20 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.41 | $124.82 |
| 52-week low | $8.72 | $50.07 |
| Distance from 52-week high | -45.60% | -36.74% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +111.27% | +64.54% |
| Average volume | 399.18K | 213.15K |
| Shares outstanding | 37.14M | 6.71M |
| Employees | 69 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed MNPR by 31.9 percentage points over the past year.
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Monopar Therapeutics
MNPR stock →Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
CBIO vs MNPR FAQ
Which is bigger, Crescent Biopharma or Monopar Therapeutics?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $553.86M compared with $529.99M for Monopar Therapeutics (MNPR).
Which stock has performed better over the past year, CBIO or MNPR?
CBIO returned +17.08% over the past 12 months, compared with -14.80% for MNPR (price return, excluding dividends). Past performance does not predict future results.
Are Crescent Biopharma and Monopar Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.